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OBJECTIVE — To test the hypothesis that age of type 2 diabetes onset inﬂuences inherent
susceptibility to diabetic retinopathy, independent of disease duration and degree of hypergly-
cemia.
RESEARCH DESIGN AND METHODS — Retinopathy data from 624 patients with a
type 2 diabetes duration of 20–30 years (group A) were analyzed by stratifying patients accord-
ing to age of onset of diabetes and glycemic control. Retinopathy status was scored clinically as
per a modiﬁed Early Treatment Diabetic Retinopathy Study (ETDRS) severity scale. To obviate
possible bias due to a higher attrition from comorbidities in those with later-onset diabetes and
retinopathy, 852 patients with type 2 diabetes of shorter duration (10–12 years, group B) were
similarly studied.
RESULTS — Prevalence and severity of retinopathy was signiﬁcantly higher in the younger-
onset, group A patients. When further stratiﬁed according to mean A1C, retinopathy risk re-
mained increased in younger-onset patients. The greatest impact was seen in those with a mean
A1C 9% (odds ratio [OR] for retinopathy 16.6, 7.5, and 2.7 for age of diagnosis 45, 45–55,
and 55 years, respectively, P  0.003). By logistic regression, earlier type 2 diabetes onset is
associated with increased retinopathy risk, independent of traditional risk factors (OR of reti-
nopathy1.9,1.1,and1forageofonset45,45–55,and55years,respectively).Similarresults
were found in group B patients.
CONCLUSIONS — These data suggest an increased inherent susceptibility to diabetic ret-
inopathy with earlier-onset type 2 diabetes. This further supports the importance of delaying
developmentofdiabetesandalsoimpliesaneedformorestringentmetabolictargetsforyounger
individuals.
Diabetes Care 31:1985–1990, 2008
S
uperimposed on the worldwide ep-
idemic of diabetes that we are cur-
rently facing is the demographic
trend to an ever younger age of diagnosis
of type 2 diabetes (1). In recent studies,
type 2 diabetes constitutes up to 45% of
incidentpediatricdiabetes,and7–22%of
adolescent diabetes presents with diabe-
tes-speciﬁc complications at diagnosis
(2,3). To date, few studies have examined
long-term outcomes as a function of age
of diagnosis in type 2 diabetes, and even
fewer have looked at the development of
retinopathy speciﬁcally. There is some
limited data suggesting that young-onset
diabetes is associated with an increased
risk for complications compared with lat-
er-onset diabetes (4) and that the devel-
opmentandprogressionofcomplications
might be particularly rapid in early-onset
disease (2). What is hitherto unknown is
whethertheincreasedprevalenceofcom-
plications associated with early-onset dis-
easeissimplyaconsequenceofthelonger
duration of disease, a consequence of a
more severe metabolic phenotype, or in
fact something speciﬁc to the diabetic mi-
lieuinyoungerpatientsthatmakestissues
more inherently susceptible to hypergly-
cemic damage.
We therefore explore the hypothesis
that in type 2 diabetes, susceptibility to
retinopathy is dependent on age of diabe-
tes onset. The isolated effect of age of di-
abetes onset on long-term retinopathy
status was examined independent of du-
ration of diabetes and glycemic control,
the two most important risk factors for
retinopathy.
RESEARCH DESIGN AND
METHODS— Data from 8,301 pa-
tients with type 2 diabetes referred to the
Royal Prince Alfred Hospital Diabetes
CentreinSydney,Australia,from1989to
2007 were available for study. These pa-
tients had a full complications assess-
ment, and data were collected following a
standardized protocol as described previ-
ously (5). Speciﬁc information collected
at each assessment includes demographic
details,ageofdiagnosis,A1C,BMI,lipids,
blood pressure, and albuminuria. Reti-
nopathystatuswasassessedbydirectfun-
doscopy through dilated pupils or from
reportbythetreatingophthalmologist(in
10%ofcases).Severityofretinopathywas
scored as per a modiﬁed Early Treatment
Diabetic Retinopathy Study (ETDRS) se-
verity scale (6) into the following catego-
ries: 1) nil, 2) nonproliferative (minimal,
mild-moderate, or severe), or 3) prolifer-
ative, each with or without 4) macular
edema. Those with either of the last two
categories were considered as having “vi-
sion-threatening retinopathy.”
Toassesstheimpactofageofonseton
long-term retinopathy status, indepen-
dent of duration, data from 624 patients
with duration of 20–30 years of known
type 2 diabetes at last follow-up, were an-
alyzed(groupA).Toobviatepossiblebias
due to a higher attrition from comorbidi-
ties in those with later-onset diabetes and
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abetes of shorter duration (10–12 years,
group B), and therefore younger in age,
were similarly studied.
Data were analyzed by grouping pa-
tients according to the presence or ab-
sence of retinopathy at the last visit and
then further stratiﬁed by age of onset and
mean A1C over all visits (mean  SD vis-
its: group A 3.8  3.2 and group B 2.8 
2.3). Other clinical data were taken from
the patient’s last visit. The presence of
metabolic syndrome was deﬁned by
World Health Organization criteria (7).
Statistical analyses
Data were analyzed using NCSS 2004
software. Data for group A and group B
were each grouped according to age of
diagnosis of diabetes: 45, 45–55, and
55 years. A1C was also categorized:
7.0, 7.0–9.0, and 9.0%. These A1C
categories were chosen to represent those
withgood,suboptimal,andverypoorgly-
cemic control. Continuous data were
checked for normality and are presented
as mean or median. Kruskal-Wallace
ANOVA was used to compare means or
medians. Categorical data were presented
as percentage and 95% CI. 
2, Fisher’s
exact test, and odds ratios were used to
compare the groups. To assess whether
there was any increasing or decreasing
trendbetweenthegroups,atrendtestwas
performed. Logistic regression was used
to determine the independent predictors
for retinopathy both as continuous and
categorical variables. Independent deter-
minants used were age, age of diagnosis
(asacategoricalvariableinmodel1andas
a continuous variable in model 2), A1C,
weight, metabolic syndrome (as individ-
ual factors and as a dichotomous vari-
able), duration of diabetes, sex, ethnicity,
and family history of diabetes. A stepwise
forward method was used, and variables
that were signiﬁcant using the log likeli-
hood method were included in the ﬁnal
model. Interactions were tested between
the independent variables.
RESULTS
Increase in the prevalence and
severity of retinopathy in those with
a younger age of diabetes onset
The demographic proﬁle of those with a
long duration (group A) and those with a
moderate duration (group B) of diabetes,
stratiﬁed by age of diagnosis, is shown in
Table 1. For group A, there was an ap-
proximate threefold excess of retinopathy
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Age of diabetes onset and retinopathy risk
1986 DIABETES CARE, VOLUME 31, NUMBER 10, OCTOBER 2008in those with early-onset disease (45
years), including a notable excess in
vision-threatening retinopathy. For group
B, the older-onset group again had the
lowestprevalenceofretinopathy,whereas
the 45- and the 45- to 55-year onset
groups were not statistically different
from one another (
2  0.3; P  0.6).
Glycemicexposurewasslightlylessfavor-
ableintheearly-onsetgroups,butthedif-
ferences in A1C were small, at 0.2% for
group A and 0.8% for group B. There was
nodifferenceintheprevalenceofthemet-
abolic syndrome between the groups. For
group A, the younger patients are receiv-
ing more antihypertensive treatment, but
blood pressure remains similar between
the age-of-onset groups.
Increase in the prevalence of
retinopathy in those with younger
age of onset: adjustment for
glycemic exposure
Two approaches were used to address the
extent to which excess of retinopathy in
early-onset groups was due to slightly
poorer glycemic control. First, retinopa-
thyriskwasstratiﬁedbyaverageA1C.Ta-
ble 2 and Fig. 1 show the prevalence and
ORsofretinopathyforeachageofonsetat
each level of glycemic exposure for the
duration cohorts. The impact of the
younger age of diagnosis is greatest in
those with the worst long-term glycemic
control (mean A1C 9%), with at least a
two- to threefold increase in the OR of
retinopathyforthosediagnosedbefore45
years of age compared with those of sim-
ilar disease duration and glycemic expo-
sure but diagnosed at 55 years of age.
However, this trend of differing retinopa-
thyprevalenceaccordingtoageofonsetis
alsoseenatlowerlevelsofglycemicexpo-
sure, even into the target range of A1C
7% (Table 2). The oldest-onset group
invariably had the lowest risk of retinop-
athy. Second, regression analysis shows
that each 1% rise in A1C is associated
with a 13.9% increase in retinopathy for
themaincohortofinterest(groupA).The
small difference in A1C between the sub-
groups can only account for 12% of the
observed difference in the prevalence of
retinopathy between the youngest- and
the oldest-onset group.
Age of diagnosis is an independent
predictor of long-term retinopathy
Table 3 shows the results of logistic re-
gression analysis for both duration co-
horts. There is a signiﬁcant effect of age of
diagnosis, irrespective of whether it was
considered as a categorical variable
(model 1 OR of retinopathy: 1.9, 1.1, and
1 for age of onset 45, 45–55, and 55
years, respectively, for group A with dia-
betes duration 20–30 years) or a contin-
uousvariable(model2ORofretinopathy:
0.88 [95% CI 0.83–0.94] for Group A).
These ﬁndings were independent of A1C,
hypertension, and other risk factors.
CONCLUSIONS— In this popula-
tion with long-duration type 2 diabetes,
patients with diabetes diagnosed at 45
years of age have a higher prevalence and
more severe grades of diabetic retinopa-
thy than those diagnosed later, despite
matched duration of diabetes and glyce-
mic control. Although before stratiﬁca-
tion, glycemic load was slightly more
unfavorable in the youngest age-of-onset
group, the difference in A1C was very
small and in our opinion not sufﬁcient to
explain the rather large difference in risk
of retinopathy. Moreover, the increased
prevalence of retinopathy in the younger
age-of-onset groups persists within each
level of glycemic control. The impact of
age of onset on retinopathy risk is the
highest in those diagnosed before 45
years of age who have a mean A1C of
9%.Multivariateregressionanalysisad-
justing for other traditional retinopathy
risk factors indicate that the age of onset
of diabetes is an independent risk factor
for the development of retinopathy.
These data support earlier studies
that suggest early-onset type 2 diabetes as
a more aggressive disease (2,4,8).
Younger patients obviously would have,
on average, a longer life-time exposure to
hyperglycemia and would be likely to
have worse glycemic control. Both are
known to be strong risk factors for reti-
nopathy.Moreintriguingly,however,isthe
independent effect of age at onset on reti-
nopathy risk revealed by our analysis. This
suggests that there are additional factors
hitherto unexplored in younger individuals
that predispose to retinopathy.
It is interesting to note that the land-
mark Diabetes Control and Complica-
tions Trial (DCCT) and Epidemiology of
Diabetes Interventions and Complica-
tions (EDIC) trial have demonstrated that
metabolic control achieved early in the
course of type 1 diabetes is effective at
reducing microvascular complications
riskandthatthebeneﬁtextendsforacon-
siderable period beyond the time that
tight glycemic control was maintained
under the strict protocol of the study (9–
11). Some have ascribed the “metabolic
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trial as perhaps due to persistent suppres-
sionofinﬂammationandadvancedglyca-
tion end product formation. In light of
our data, a supplementary hypothesis
could be that the age at which tissues are
exposed to hyperglycemic insult is a de-
terminant of the detrimental response. In
this scenario, the DCCT control group
would always be more at risk of compli-
cations by being exposed to hyperglyce-
mia at a younger age. Interestingly, levels
of vascular endothelial growth factor
(VEGF) and IGF-I, both potent angio-
genic growth factors implicated in the de-
velopment of diabetic retinopathy, have
been found to vary with age in diabetes
(12,13). Additionally, the VEGF expres-
sion in response to a stimulus is lessened
in older versus younger individuals (14).
Conceivably, ocular VEGF response to
hypoxia and hyperglycemia may be
greater in the younger patients, predis-
posing them to the development of reti-
nopathy. This, however, remains purely
speculative and would be an interesting
avenue for future research.
One of the strengths of our study is
the long duration of diabetes in our co-
horts, made possible by our systematic
computerized database of more than 20
years of data. Even in our short-duration
cohort (group B), the mean duration of
diabetes was greater than 10 years, and in
the longer duration cohort (group A), di-
abetes had been present in every subject
for over 20 years. The long duration en-
suressufﬁcienttimeforretinopathytode-
velop. One previous study of newly
diagnosed type 2 diabetes examined the
impact of age of diagnosis on retinopathy
risk (4) but did not show any relationship
betweenretinopathyandageofdiagnosis.
This study, however, had a mean fol-
low-up of only 3.9 years, which is too
short a time to see a meaningful effect on
retinopathy development. A recent study
of early-onset type 2 diabetes in Asians
found that diabetes duration but not age
of onset was a risk factor for microvascu-
lar complications (15); however, as age of
onset and duration of diabetes are so in-
herently linked, it is hard to demonstrate
an independent effect if both are entered
into a statistical model. Donaghue et al.
(16) found that retinopathy was more
prevalent in adolescents with type 1 dia-
betes than in those with type 2 diabetes
(20 vs. 4%); disease duration was, how-
ever, very different between the two
groups, making comparisons difﬁcult.
Our study design of comparing cohorts
with equal and long duration of disease
helped to tease out effects independent of
disease duration and was made possible
by collecting data consistently and in the
samemanneroveralongerperiodoftime.
In the elegant 50-year Medalist study
by King et al. (17), which examined reti-
nopathy prevalence in type 1 diabetes of
extreme long duration, mean age of onset
was lower in the retinopathy group; al-
though this was not found to be statisti-
cally signiﬁcant, Krakoff et al. (18) found
a reduced risk of retinopathy in a Pima
Indian population with youth-onset dia-
betes compared with later-onset diabetes.
Their subjects were those diagnosed be-
fore 20 years of age, a much younger on-
set cohort than in our study. Thus, it is
possible that our ﬁndings are not able to
be generalized to type 1 diabetes and ad-
Figure1—GroupA(durationoftype2diabetes20–30years):ORforretinopathygroupedbyage
of diagnosis and mean A1C. Reference group is age of diagnosis 55 years and A1C 7%.
Table 3—Predictors for retinopathy by logistic regression analysis
Variable
Group A: duration of type 2
diabetes 20–30 years
Group B: duration of type 2
diabetes 10–12 years
OR ( 95% CI) P OR (95% CI) P
Model 1
Age diagnosed (years)
45 1.9 (1.1–3.6) 0.04 1.8 (1.2–2.7) 0.0003
45–55 1.1 (0.6–2.1) 0.8 2.2 (1.6–3.2) 0.0001
55 1 1
A1C (%)
7.0 1 1
7–9 2.2 (1.2–3.6) 0.002 2.1 (1.4–3.1) 0.0003
9.0 3.0 (1.7–5.3) 0.0002 3.6 (2.4–5.5) 0.0001
Hypertension 2.1 (1.3–2.7) 0.003 NS
Ethnicity 1.9 (1.2–2.7) 0.004 NS
Weight (kg) 1.01 (1.00–1.02) 0.045 NS
Model 2
Age diagnosed (years) 0.88 (0.83–0.94) 0.0001 0.7 (0.6–0.9) 0.03
A1C (%) 1.3 (1.2–1.5) 0.0001 1.3 (1.2–1.4) 0.0001
Hypertension 2.0 (1.2–3.2) 0.01 NS
Age (years) 1.1 (1.0–1.2) 0.002 1.3 (1.02–1.7) 0.04
Weight (kg) 1.01 (1.03–1.03) 0.03 NS
Ethnicity 1.8 (1.2–2.7) 0.005 NS
Age of diabetes onset and retinopathy risk
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betes, as these years may not contribute
equally to risk of complications.
Our ﬁndings are not without caveats.
Retinal photography is undoubtedly the
goldstandardfordiagnosisandclassiﬁca-
tion of diabetic retinopathy. While this is
ideal,itwouldbelogisticallyverydifﬁcult
toimplementinthisstudy,particularlyas
the data collection span over a period of
two decades and began at a time when
retinal photography was not freely avail-
ableasaclinicaltool.Moreover,ourstudy
has the extremely stringent inclusion cri-
teria of a very long and standardized du-
ration of diabetes. It would be impossible
to predict which patient will survive long
enough to fulﬁll this criteria; thus, it
would be difﬁcult to photograph a man-
ageable-sized cohort to test our hypothe-
sis in a prospective manner. In our study,
thediagnosisandclassiﬁcationofretinop-
athy was performed by a single physician
(D.K.Y.) in 50–60% of cases. This physi-
cian has demonstrated and published
goodagreementwithophthalmologistsin
the detection and assessment of retinopa-
thy (19). Due to the organizational struc-
ture of our clinics, over a period of nearly
two decades, only ﬁve experienced spe-
cialist endocrinologists were responsible
forexaminingthe30–40%ofthepatients
not examined by either D.K.Y. or an oph-
thalmologist. All endocrinologists re-
ceived the same training in fundoscopy
and classiﬁcation of retinopathy using a
simpleclinicalguideline.Therewasalso
no evidence of a statistically signiﬁcant
difference in the distribution of the var-
iousexaminersamongthedifferentage-
groupsofpatientsthathadbeenstudied
(data not shown). Instead of relying on
retrospective interpretation of clinical
records, the retinal ﬁndings were pro-
spectively categorized and entered into
a purpose-designed computer database
over a time span of two decades. Al-
though differing sensitivities in the
detection of retinopathy or misclassiﬁ-
cation of retinopathy cannot be com-
pletely discounted as a source of bias, it
is minimized by the above-mentioned
factors.
As mentioned previously, it is possi-
ble that the presence of retinopathy is as-
sociatedwithanexcessmortalityrisk(20)
and therefore a preferential drop out of
older patients with retinopathy. This
would introduce an ascertainment bias
and reduce the number of later-onset in-
dividuals with retinopathy. We tried to
assess the magnitude of this confounding
effectbystudyingtwocohortswithdiffer-
ent disease durations. The group with the
shorter duration of diabetes, which
would be expected to have less retinop-
athy associated mortality, nevertheless
showedthesametrendofmoreretinop-
athy in the younger-onset group. We
consider this as supporting evidence
that what we have observed is a true
phenomenon. However, we cannot dis-
count the possibility that for younger
patients, the metabolically severe cases
are more likely to be diagnosed and
preferentially referred to our clinic, re-
sulting in bias toward detection of more
youth with retinopathy.
In summary, this study shows that
early onset of type 2 diabetes is an inde-
pendent risk factor for the development
of diabetic retinopathy. This suggests an
increased inherent tissue susceptibility to
thedamagingeffectsofhyperglycemiaata
younger age. This further supports the
importance of delaying the onset of dia-
betes even if it cannot be completely pre-
vented. It also implies a need for more
stringent metabolic targets for younger
individuals in the early years after diabe-
tes onset.
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